NCT05806853View on ClinicalTrials.gov

PET/MR for Prostate Cancer Restaging: a Phase II Prospective Monocentric Study

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 3, 2020

Primary Completion Date

October 5, 2022

Study Completion Date

October 5, 2022

Conditions
Prostate Cancer
Interventions
DRUG

68Ga-PSMA

Glu-NH-CO-NH-Lys-(Ahx)-\[68Ga(HBED-CC)\] (68Ga-PSMA)

DRUG

68Ga-RM2

Bombesin receptor antagonist (68Ga-RM2)

Trial Locations (1)

20132

IRCCS Ospedale San Raffaele, Milan

All Listed Sponsors
lead

IRCCS San Raffaele

OTHER

NCT05806853 - PET/MR for Prostate Cancer Restaging: a Phase II Prospective Monocentric Study | Biotech Hunter | Biotech Hunter